BioCryst Pharmaceuticals vs Halozyme Therapeutics
BCRX and HALO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCRX and HALO compare
Halozyme Therapeutics is the larger company, worth 6.9 times as much as BioCryst Pharmaceuticals ($14.9B against $2.2B).
BioCryst Pharmaceuticals grew revenue faster over the last twelve months (68.7% versus 41.2% for Halozyme Therapeutics).
Halozyme Therapeutics keeps more of each dollar of sales as profit, with a net margin of 24.9% compared with −40.9% at BioCryst Pharmaceuticals.
Halozyme Therapeutics scores higher on the StockData Score (13 against 9 for BioCryst Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCRX | HALO |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $14.9B |
| Share price | $8.47 | $130.91 |
| Change, 1 year | 15.9% | 101% |
| Change, 5 years | −31.7% | 222% |
| Beta (5Y) | 0.80 | 0.71 |
| Employees | 435 | 423 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 4 | 4 |
| Performance score | 2 | 5 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 38.6× |
| P/S | 2.3× (better) | 8.9× |
| P/B | – | 104× |
| EV/EBITDA | – | 27.5× |
| P/FCF | 5.8× (better) | 18.4× |
| PEG | – | 1.83 |
| FCF yield | 17.3% (better) | 5.4% |
| Fair value | – | $69.98 |
| Margin of safety | – | −87.1% |
| Growth | ||
| Revenue growth (TTM) | 68.7% (better) | 41.2% |
| Revenue growth, 5Y average | 118% (better) | 39.2% |
| Net income growth (TTM) | – | −25.8% |
| EPS growth (TTM) | – | −22.4% |
| EPS growth, 5Y average | – | 23.0% |
| Profitability | ||
| Gross margin | 97.8% (better) | 82.4% |
| Operating margin | −33.3% | 35.9% (better) |
| Net margin | −40.9% | 24.9% (better) |
| FCF margin | 39.7% | 48.5% (better) |
| Return on equity | – | 174% |
| Return on invested capital | – | 21.7% |
| Financial health | ||
| Debt / equity | – | 14.95 |
| Net debt / EBITDA | – | 3.24 |
| Interest coverage | −4.2× | 29.4× (better) |
| Current ratio | 2.32 | 2.71 (better) |
| Altman Z-score | −3.68 | 5.43 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 103% | 109% |
| Held by insiders | 1.9% | 1.3% |
| Insider net buying, 12 months | −$4.1M (better) | −$41.2M |
| Short interest, % of float | 11.0% | 13.7% |
Go deeper
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
- HALO stock overview
- HALO income statement
- HALO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.